SCHEMBL2225334

SCHEMBL2225334

O=S(=O)(NC1CC1)c1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.67
RECQL P46063 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
PARG Q86W56 1/20 0.59
CTSB P07858 3/20 0.57
CTSK P43235 3/20 0.57
UCHL1 P09936 2/20 0.57
CTSS P25774 2/20 0.57
CTSC P53634 2/20 0.57
USP30 Q70CQ3 2/20 0.57
CTSL P07711 1/20 0.57
PSEN1 P49768 1/20 0.56
PSEN2 P49810 1/20 0.56
APH1B Q8WW43 1/20 0.56
NCSTN Q92542 1/20 0.56
APH1A Q96BI3 1/20 0.56
PSENEN Q9NZ42 1/20 0.56
MMP2 P08253 1/20 0.56
MMP9 P14780 1/20 0.56
MMP13 P45452 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8355420 1.00 KDM4E (0.67) KDM4ERECQLSMN1; SMN2PARGCTSB
Hydrochloric Acid SCHEMBL15687975 0.98 KDM4E (0.64) KDM4ERECQLSMN1; SMN2PARGCTSB
SCHEMBL4041413 0.92 KDM4E (0.74) KDM4ERECQLSMN1; SMN2CTSBCTSK
SCHEMBL7648169 0.92 KDM4E (0.81) KDM4ERECQLSMN1; SMN2MMP2MMP9
SCHEMBL1722677 0.91 KDM4E (0.56) KDM4ERECQLSMN1; SMN2PARGCTSB
SCHEMBL9835393 0.91 KDM4E (0.56) KDM4ERECQLSMN1; SMN2PARGCTSB
SCHEMBL3066034 0.91 KDM4E (0.56) KDM4ERECQLSMN1; SMN2PARGCTSB
SCHEMBL11372059 0.91 LMNA (0.56) KDM4ERECQLSMN1; SMN2PARGCTSB
SCHEMBL12852936 0.91 KDM4E (0.56) KDM4ERECQLSMN1; SMN2PARGCTSB
SCHEMBL812698 0.90 SMN1; SMN2 (0.78) KDM4ERECQLSMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 CN claimed
WO-2023055124-A1 BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사유한양행 2023-04-06 WO claimed
EP-3433234-A1 ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS Merck Sharp & Dohme Corp. (US) 2019-01-30 EP claimed
WO-2017165256-A1 ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS MERCK SHARP & DOHME CORP. (US) 2017-09-28 WO claimed
WO-2008100564-A1 LTA4H MODULATORS AND USES THEROF JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-21 WO claimed
EP-4716529-A2 COMPOUNDS THAT RE-ACTIVATE MUTANT P53 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) 2026-04-01 EP disclosed
EP-4501928-A1 THIAZOLE DERIVATIVE COMPOUND AND USES THEREOF Autotelic Bio Inc. (KR) 2025-02-05 EP disclosed
US-12187684-B2 Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2025-01-07 US disclosed
CN-115697993-B Pyrimidine compounds as AXL inhibitors 南京正大天晴制药有限公司 2024-12-10 CN disclosed
WO-2024243343-A2 COMPOUNDS THAT RE-ACTIVATE MUTANT P53 KARANICOLAS JOHN (US) 2024-11-28 WO disclosed
WO-2024201308-A1 NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR 주식회사 엘지화학 2024-10-03 WO disclosed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 CN disclosed
EP-1461035-A4 SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2005-04-06 EP disclosed
EP-1461035-A2 SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS Bristol-Myers Squibb Company (US) 2004-09-29 EP disclosed
WO-2003053344-A2 SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed
US-5864043-A CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST KARL THOMAE GMBH (DE) 1999-01-26 US disclosed
US-5541229-A ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1996-07-30 US disclosed
EP-0376870-A1 A new organosilylpolyphosphoric reagent, its preparation and application to the process of synthesis of 3-carboxyquinolones or azaquinolones and their salts CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) 1990-07-04 EP disclosed
US-4053458-A INHIBITORS UOP INC. (US) 1977-10-11 US disclosed
US-4022828-A BIS-(SULFONAMIDO)-SULFIDES UNIVERSAL OIL PRODUCTS COMPANY (US) 1977-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187684-B2 Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof RORC, RORB, RORA KDM4E 2234/4885RECQL 2993/4885SMN1; SMN2 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.